Can dupilumab heal the skin barrier in eczema patients?

NCT ID NCT04447417

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether dupilumab, an injected drug for eczema, improves skin barrier function in 52 people with moderate to severe atopic dermatitis. Researchers measured water loss from the skin after tape stripping to assess barrier repair over 16 weeks. The goal was to see if the drug helps restore the skin's protective layer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dupilumab (injection)
What this could lead to: If successful, this could show that dupilumab helps repair the skin barrier in eczema patients, pointing toward better long-term disease control.
What could go wrong: This is a small, completed phase 4 study with no placebo group, so results may not apply to everyone. It focuses on skin measurements, not long-term symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Investigational Site Number 1240001

Montreal, H2X 2V1, Canada
Investigational Site Number 8400001

Denver, Colorado, 80206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.